Immix Biopharma, Inc. Common Stock (IMMX) Stock Price

IMMXStock
$14.47+521.46%52W
Market Cap$1.03B
P/E
PEG Ratio
Div yield
Beta0.14

IMMX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)63.91%
Price vs S&P 500 (4W)58.20%
VGM Score93.38

IMMX Earnings Surprise History

Q2 25-0.22est. -0.16
Q3 25-0.24est. -0.19
Q4 25-0.28est. -0.16
Q1 26-0.18est. -0.21
Q2 26-0.18est. -0.18

IMMX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.17
4.15

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
IMMXImmix Biopharma, Inc. Common Stock
A$14.47
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About Immix Biopharma, Inc. Common Stock

Immix Biopharma is a clinical-stage biopharmaceutical company developing novel cell therapies for oncology and inflammatory diseases using its proprietary TME Normalization Technology. This platform enables therapeutics to penetrate tumors and simultaneously target multiple components of the tumor microenvironment. The company's pipeline includes CAR-T candidate NXC-201 for autoimmune diseases and IMX-110 for soft tissue sarcoma.